{"organizations": [], "uuid": "317e96f35b0f57c656524b835dbbaf91798d72f8", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "in.reuters.com", "main_image": "https://s3.reutersmedia.net/resources/r/?m=02&d=20180508&t=2&i=1259636610&w=1200&r=LYNXMPEE470BP", "site_section": "http://feeds.reuters.com/reuters/INhealth\r", "section_title": "Reuters: Health", "url": "https://in.reuters.com/article/us-astrazeneca-m-a-luye-pharma-grp/astrazeneca-sells-rights-for-seroquel-to-luye-pharma-for-538-million-idINKBN1I90IO", "country": "US", "domain_rank": 408, "title": "AstraZeneca sells rights for Seroquel to Luye Pharma for $538 million", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-08T09:26:00.000+03:00", "replies_count": 0, "uuid": "317e96f35b0f57c656524b835dbbaf91798d72f8"}, "author": "", "url": "https://in.reuters.com/article/us-astrazeneca-m-a-luye-pharma-grp/astrazeneca-sells-rights-for-seroquel-to-luye-pharma-for-538-million-idINKBN1I90IO", "ord_in_thread": 0, "title": "AstraZeneca sells rights for Seroquel to Luye Pharma for $538 million", "locations": [], "entities": {"persons": [{"name": "luye pharma", "sentiment": "negative"}, {"name": "sarah young", "sentiment": "none"}, {"name": "james davey", "sentiment": "none"}, {"name": "mark mallon", "sentiment": "none"}], "locations": [{"name": "london", "sentiment": "none"}, {"name": "uk", "sentiment": "none"}, {"name": "china", "sentiment": "none"}, {"name": "london", "sentiment": "none"}], "organizations": [{"name": "luye pharma", "sentiment": "negative"}, {"name": "astrazeneca", "sentiment": "negative"}, {"name": "seroquel xr", "sentiment": "none"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "luye pharma group", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "astra", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 8, 2018 / 6:27 AM / Updated 10 hours ago AstraZeneca sells rights for Seroquel to Luye Pharma for $538 million Reuters Staff 1 Min Read\nLONDON (Reuters) - British pharma company AstraZeneca said it had sold the rights for Seroquel, a treatment for schizophrenia and bipolar disease, to Luye Pharma Group for $538 million, as part of a strategy to focus on other therapy areas. FILE PHOTO: The logo of AstraZeneca is seen on medication packages in a pharmacy in London April 28, 2014. REUTERS/Stefan Wermuth/File Photo\nAstraZeneca said it had sold the rights for the treatments, named Seroquel and Seroquel XR, in the UK, China and other international markets, in a deal which will give it $260 million once the transaction closes, followed by future payments.\n“The agreement with Luye Pharma is in line with AstraZeneca’s strategy to focus on three main therapy areas while maximising the value from our legacy medicines like Seroquel,” said Astra’s executive vice president Mark Mallon in a statement on Tuesday. Reporting by Sarah Young, editing by James Davey", "external_links": [], "published": "2018-05-08T09:26:00.000+03:00", "crawled": "2018-05-08T10:02:53.003+03:00", "highlightTitle": ""}